Ligand Pharmaceuticals Incorporated (NASDAQ:LGND - Get Free Report) CFO Octavio Espinoza sold 5,000 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $115.03, for a total value of $575,150.00. Following the completion of the sale, the chief financial officer now owns 18,879 shares in the company, valued at approximately $2,171,651.37. This represents a 20.94 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Octavio Espinoza also recently made the following trade(s):
- On Monday, December 23rd, Octavio Espinoza sold 2,104 shares of Ligand Pharmaceuticals stock. The stock was sold at an average price of $116.37, for a total value of $244,842.48.
Ligand Pharmaceuticals Stock Up 0.5 %
NASDAQ LGND opened at $116.00 on Friday. Ligand Pharmaceuticals Incorporated has a 12-month low of $67.72 and a 12-month high of $129.90. The company's 50 day moving average is $114.23 and its 200-day moving average is $111.48. The firm has a market cap of $2.19 billion, a P/E ratio of 46.22 and a beta of 1.04.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Yousif Capital Management LLC grew its holdings in shares of Ligand Pharmaceuticals by 1.4% in the fourth quarter. Yousif Capital Management LLC now owns 7,193 shares of the biotechnology company's stock worth $771,000 after purchasing an additional 96 shares during the last quarter. US Bancorp DE grew its stake in Ligand Pharmaceuticals by 14.8% in the fourth quarter. US Bancorp DE now owns 758 shares of the biotechnology company's stock worth $81,000 after purchasing an additional 98 shares during the period. Creative Planning lifted its position in Ligand Pharmaceuticals by 4.0% during the 3rd quarter. Creative Planning now owns 2,896 shares of the biotechnology company's stock valued at $290,000 after acquiring an additional 111 shares during the period. Mutual of America Capital Management LLC grew its stake in shares of Ligand Pharmaceuticals by 4.2% in the 4th quarter. Mutual of America Capital Management LLC now owns 2,862 shares of the biotechnology company's stock worth $307,000 after buying an additional 115 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in shares of Ligand Pharmaceuticals by 23.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 661 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 125 shares during the last quarter. 91.28% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have weighed in on LGND. HC Wainwright reiterated a "buy" rating on shares of Ligand Pharmaceuticals in a report on Wednesday, December 11th. Benchmark reissued a "buy" rating and issued a $135.00 target price on shares of Ligand Pharmaceuticals in a research note on Monday, December 23rd. Barclays lifted their target price on Ligand Pharmaceuticals from $150.00 to $160.00 and gave the stock an "overweight" rating in a research note on Monday, December 16th. Oppenheimer lifted their price target on Ligand Pharmaceuticals from $135.00 to $147.00 and gave the stock an "outperform" rating in a report on Friday, November 8th. Finally, Royal Bank of Canada increased their price objective on Ligand Pharmaceuticals from $141.00 to $143.00 and gave the stock an "outperform" rating in a research report on Wednesday, December 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Ligand Pharmaceuticals currently has a consensus rating of "Buy" and a consensus target price of $147.00.
Read Our Latest Research Report on LGND
Ligand Pharmaceuticals Company Profile
(
Get Free Report)
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
